Globus Medical Q1 Revenue Jumps 27%, Beats Estimates, Raises Full-Year EPS Guidance
Summary
Globus Medical reported robust first-quarter results, with revenue surging 27% to $759.9 million, significantly surpassing analyst estimates of $737 million. Adjusted EPS also beat expectations, rising 65% to $1.12 against a consensus of $0.92. This strong performance, driven by core spine growth and contributions from the Nevro acquisition, represents an acceleration compared to the 16.7% net sales increase reported in the prior 2025 10-K. Crucially, the company raised its full-year 2026 non-GAAP diluted EPS guidance to $4.70-$4.80 from $4.40-$4.50, signaling increased confidence in future profitability and operational efficiency. This comprehensive beat and guidance raise are highly material and likely to drive significant positive stock movement, requiring immediate attention from traders. Investors will now focus on the continued successful integration of Nevro and sustained organic growth momentum.
At the time of this announcement, GMED was trading at $91.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $51.79 to $101.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.